Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Multiple Myeloma Channel is supported with funding from BMS (Gold) and Legend Biotech (Bronze).

VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.

Share this video  

EMN 2018 | How to treat high-risk mutated myeloma

Nikhil Munshi • 19 Apr 2018
EMN 2018
Multiple Myeloma

Nikhil Munshi, MD, of the Dana-Farber Cancer Institute, Boston, MA, discusses considerations in the treatment of high risk multiple myeloma (MM) from the 1st European Myeloma Network (EMN) Meeting, in Turin, Italy. He covers more agressive therapy options, as well as intergrating our increased knowledge of genomics to improve treatment.

More from Nikhil Munshi

A novel CAR T-cell therapy targeting the intracellular protein MZB1 for multiple myeloma
2:21
A novel CAR T-cell therapy targeting the intracellular protein MZB1 for multiple myeloma
Nikhil Munshi • 6 Dec 2025
Functional fitness of CAR T-cells in the bone marrow following durcabtagene autoleucel in RRMM
1:44
Functional fitness of CAR T-cells in the bone marrow following durcabtagene autoleucel in RRMM
Nikhil Munshi • 6 Dec 2025
The interaction between bone marrow stromal cells and tumor cells as a potential target in WM
1:32
The interaction between bone marrow stromal cells and tumor cells as a potential target in WM
Nikhil Munshi • 19 Oct 2024
Immunotherapies in the future treatment landscape for Waldenström's macroglobulinemia
1:04
Immunotherapies in the future treatment landscape for Waldenström's macroglobulinemia
Nikhil Munshi • 19 Oct 2024

Related Videos

Updated results from the iMMagine-1 trial of anito-cel in R/R multiple myeloma
4:32
Updated results from the iMMagine-1 trial of anito-cel in R/R multiple myeloma
Nikhil Munshi • 18 Dec 2025
Investigating AZD0120, a dual-targeting CAR-T product, in R/R myeloma: DURGA-1 preliminary results
3:36
Investigating AZD0120, a dual-targeting CAR-T product, in R/R myeloma: DURGA-1 preliminary results
Nikhil Munshi • 7 Dec 2025
A Phase II trial investigating IberKDd in R/R multiple myeloma: the ReKInDLE study
3:11
A Phase II trial investigating IberKDd in R/R multiple myeloma: the ReKInDLE study
Nikhil Munshi • 7 Dec 2025
Remote therapeutic monitoring reduces infection-related hospitalizations in hematologic cancers
4:04
Remote therapeutic monitoring reduces infection-related hospitalizations in hematologic cancers
Nikhil Munshi • 15 Dec 2025
The content of VJHemOnc is intended for healthcare professionals